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We studied the effect of variation at the lipoprotein lipase (LPL) gene locus on the susceptibility of individuals with non-
insulin dependent diabetes mellitus (NIDDM) in a population of 110 NIDDM patients and 91 controls. Our objective was to
study the relationship between the LPL–Pvu II polymorphism and NIDDM and lipid metabolism. PCR-RFLP was used to
determine the DNA polymorphism of the sixth intron of the LPL gene. The frequencies of the genotypes in case and control
groups were 29.1 and 30.8% for Pþ/Pþ; 45.5 and 36.3% for Pþ/P; 25.5 and 33% for P/P respectively. There was no
significant difference in frequencies of genotypes between the two groups. Logistic regression analysis revealed that tria-
cylglycerol (TAG) and apolipoprotein E levels were associated with NIDDM, whereas Pvu II genotypes were not found as
independent risk factors for the disease. Overall this study demonstrates the role of the Pvu II polymorphism in the LPL gene
in modulating plasma lipid/lipoprotein levels in patients with NIDDM. Copyright # 2004 John Wiley & Sons, Ltd.
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INTRODUCTION
One of the important risk factors in the development
of NIDDM is the high level of lipids (cholesterol and
TAG) in the plasma. Although environmental factors,
for example dietary fat intake, physical activity and
smoking, influence the plasma lipids, genetic factors
also contribute to the modulation of plasma lipid
levels. Increased understanding of pathophysiology
and molecular biology has led to identification of a
number of candidate genes involved in glucose and
lipid homeostasis. Lipoprotein lipase (LPL) is a major
determinant of plasma lipoprotein profiles because it
affects all classes of lipoprotein particles. The action
of LPL is essential not only for the hydrolysis of TAGs
in chylomicrons and very low density lipoproteins
(VLDL) but also for the maturation of high density
lipoproteins (HDL) and low density lipoproteins
(LDL).1,2 Human LPL is a glycoprotein of 448 amino
acids in its mature form,3 and the corresponding
gene has a span of 30 kilobases (kb) comprising 10
exons.4–6 Several DNA polymorphisms that generate
restriction fragment length polymorphisms (RFLP)
have been identified in the human LPL gene. These
include polymorphisms identified with Bam HI,7
Pvu II,7,8 Hind III,9 Bst NI,10 Bst I,11 Bgl II,12 and
Xba I.13 Pvu II polymorphism is the result of a
C!T transition in the restriction site of the LPL gene
sixth intron, 1.57 kb from the splice acceptor (SA)
site.14 The region containing the Pvu II site resembles
a splicing site in its homology to the consensus
sequence required for 30-splicing and the formation
of the lariat structure, suggesting that the C497!T
(CAG CTG)TAG CTG) change may interfere with
correct splicing of mRNA.
Trials have been carried out to explore associations
between LPL gene polymorphisms and lipoprotein
phenotypes. The results provided evidence of an asso-
ciation of the genotypes identified by the Pvu II RFLP
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with plasma TAG levels.15,16 Polymorphisms of LPL–
Pvu II have been reported to be associated with circu-
lating TAG levels in some studies15–22 but not in
others.23–26 These polymorphisms are common in
White populations.17,23,24
We evaluated the impact of Pvu II, a common
polymorphism in the LPL gene in a representative
group of type 2 diabetic Turkish subjects, and investi-
gated their influence on plasma lipids.
MATERIAL AND METHODS
Subjects
We studied 110 NIDDM patients (49 men and 63
women) who were referred to the Turkish Diabetes
Hospital, Istanbul for their routine clinical examination
(every 1–2 months). The diagnosis of NIDDM was
based on the criteria of The Expert Committee on the
diagnosis of diabetes mellitus.27 Written consent was
obtained from every patient after a full explanation
of the study, which was approved by the Ethics Com-
mittee of the University of Istanbul, Cerrahpasa Faculty
of Medicine. Control subjects consisted of 91 appar-
ently healthy people (30 men and 61 women) not tak-
ing medication, who either attended a routine health
check at a general practice or were staff of the Cerrah-
pasa Medical Faculty (Istanbul University, Turkey). No
patients in the study were related. All had normal hepa-
tic and endocrine functions and were relatively well
controlled with glycosylated haemoglobin (HbA1c)
6–7% (normal range 8%). Tobacco and alcohol
consumers were not included in the study. The patients
with macro- and microangiopathic complications were
excluded from this study. Total cholesterol, TAG,
HDL-cholesterol, LDL-cholesterol, and plasma glu-
cose levels were measured after overnight fasting.
Blood collection
Blood samples were taken between 08.00 and 10.00
hours by venipuncture after overnight fasting.
Serum was obtained after allowing samples to clot
for 30 min at room temperature followed by a
10-min centrifugation.
Analytical methods
Lipid and apolipoprotein assays. All the analytical
measurements were performed after overnight fasting.
Serum TAG and total cholesterol levels were
measured using standard enzymic methods (Merck,
Darmstadt, Germany) of automated analysis on an
AU5021 (Olympus, Merck). Serum apolipoprotein E
was determined by turbidimetry (automated Cobas-
Mira analyser, Roche, Meylan, France); serum apoli-
poprotein AI, apolipoprotein B and lipoprotein (a)
were determined by immunonephelometry on a Behr-
ing Nephelometer analyser with Behring reagents
(Behringwerke, Marburg, Germany). Sera were
analysed without pretreatment and diluted in double-
distilled water when lipid or apolipoprotein levels
exceeded reference values. Pooled sera were included
in each series of measurements for apolipoprotein E.
Between assays coefficients of variation of these
methods were 2.14, 4.66, 0.95, 1.52, 2.92, 4.34 and
1.53% respectively for total cholesterol, TAG, glu-
cose, apolipoprotein E, apolipoprotein AI, apolipo-
protein B and lipoprotein (a).
DNA analysis. Blood was drawn into tubes contain-
ing EDTA as an anticoagulant. Human DNA was
isolated from white blood cells of the subjects by a
standard salting out method.28 Polymerase chain reac-
tion (PCR) analysis of the sixth intron was performed
in a DNA thermocycler using 25 ml reaction mixtures
with commercially available buffer composed of
MgCl2, 300 mmol l
1 of deoxynucleotide tripho-
sphates (dNTPs), 5.6 mmol l1 of forward and reverse
primers, and 1.25 units of thermostable DNA poly-
merase from Thermus aquaticus. The selected
sequences for 50 and 30 oligomers were SB-75: 50-
ATG GCA CCC ATG TGT AAG GTG-30, and SB-
76: 50-GTG AAC TTC TGA TAA CAA TCT C-30.20
The quality of the PCR products was checked by
1.5% agarose gel electrophoresis (90 V h1) with a
50 bp marker. Samples of 430 bp-long PCR products
(8 ml) were then incubated with Pvu II restriction
endonuclease overnight at 37C. The digested DNA
was run on a 2% agarose gel (90 V h1). The 430-bp
product was digested to 320- and 110-bp products if a
Pvu II restriction site was present.
Statistical analysis
Statistical analyses were conducted using Unistat 5.1
software. Serum TAG and lipoprotein (a) were loga-
rithmically transformed before the analysis to obtain
a normal distribution of data. A comparison of vari-
ables between two groups or among three groups
was carried out using the unpaired t-test or one-way
ANOVA, respectively. The Hardy–Weinberg equili-
brium was tested by a chi-square test. Genotype
frequencies were estimated by a chi-square test.
The variables across the various genotypes and
groups were estimated by two-way ANOVA with an
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interaction term to test the influence of Pvu II geno-
type on the lipid profile. P values less than 0.05 were
considered significant.
RESULTS
Genotype distribution of Pvu II polymorphism and its
relation with serum lipid parameters (total cholesterol,
TAG, apolipoprotein E, apolipoprotein AI, apolipo-
protein B and Lp(a)) were investigated in a total of
110 NIDDM and 91 control unrelated subjects. The
demographic information of both patient and control
groups is given in Table 1. The frequencies of major
NIDDM risk factors are summarized in Table 2. The
frequency distributions of the risk factors examined
did not show any significant difference in the patient
and control groups. After PCR analysis, 430-bp frag-
ments were obtained by agarose gel electrophoresis.
PCR products are spliced to 320- and 110-bp frag-
ments in the presence of the respective restriction
sites. Determination of Pvu II polymorphisms by
PCR and RFLP showed the respective frequencies
for /, þ/ and þ/þ genotypes to be 25.5, 45.5,
and 29.1 in subjects with NIDDM, and 33, 36.3, and
30.8 in the control group (Table 3). The chi-square test
showed no significant difference between genotype
frequencies, the Hardy–Weinberg equilibrium was
tested on a whole study population (n¼ 201). Accord-
ing to the Hardy–Weinberg proportion, the various
genotypes are in equilibrium (chi-square¼ 2.04,
p¼ 0.361) and the proportions may remain constant
over generations.
The relationship between LPL gene Pvu II geno-
types and lipid parameters of NIDDM and control
subjects are presented in Table 4. Serum TAGs for
/, þ/, and þ/þ genotypes in subjects with
NIDDM, expressed as mean SE in mmol l1 were
1.60 0.14, 2.55 0.48, and 1.66 0.13, respec-
tively. There was also a significant difference in serum
apolipoprotein E concentrations between the Pvu II
genotypes where the lowest level was observed in
/. Other parameters did not show any significant
differences. Gender, BMI, plasma glucose, total cho-
lesterol, TAG, apolipoprotein E, apolipoprotein AI,
apolipoprotein B, smoking habit and LPL genotypes
were selected as conventional risk factors for NIDDM
to be analysed in multiple logistic regression analysis
(Table 5). Plasma glucose, apolipoprotein E and
apolipoprotein B were found as risk factors for
NIDDM whereas no such association was observed
for LPL–Pvu II genotypes.
DISCUSSION
Our present study explored the association between
Pvu II polymorphisms of the LPL gene and lipid/lipo-
protein levels in NIDDM. As far as we are aware, the
present study represents the first investigation of the
common polymorphism (Pvu II) of the lipoprotein
lipase gene in type 2 diabetic Turkish patients and
their influence on lipid parameters. To date, a number
of studies have been reported which explored possible
associations between LPL polymorphism and lipid
parameters in NIDDM.18,19,29,30 The results are not
consistent and suggest that the effect of this variant
is context-dependent (ethnicity and sex).
Hypertriacylglycerolemia and decreased adipose
tissue LPL activity occur commonly in diabetic
Table 1. Demographic information of the study groups
Patient Control
(n¼ 110) (n¼ 91)
Age (years) 57.99 0.87 55.46 1.18
BMI (kg m2) 27.39 0.41 26.84 0.44
Glucose (mmol l1) 8.25 0.35* 3.49 0.06
Total cholesterol (mmol l1) 5.46 0.24 5.42 0.14
Triacylglycerol (mmol l1) 1.82 0.13 1.75 0.09
Apolipoprotein E (mg l1) 42.31 1.40 49.24 3.36y
Apolipoprotein AI (g l1) 1.43 0.03 1.42 0.03
Apolipoprotein B (g l1) 1.15 0.03 1.13 0.03
Lp(a) (g l1) 0.15 0.01 0.18 0.02
Values are represented as meanSE. *p< 0.001; yp< 0.05.
Table 2. Risk factors for non-insulin dependent diabetes mellitus
in patients and control subjects
Diabetes n (%) Control n (%) p
Gender
Male 48 (43.2) 30 (33) n.s.
Female 63 (56.8) 61 (67) n.s.
Dyslipidaemia 25 (22.5) 17 (18.7) n.s.
Obesity 75 (67.6) 57 (62.6) n.s.
Smokers 15 (18.8) — —
The variables were compared with the 2-test among groups. n.s.,
not statistically significant.
Table 3. LPL–Pvu II genotype frequency distributions in non-
insulin dependent diabetes mellitus patients and control subjects
LPL gene Pvu II genotype frequencies
þ/ n (%) / n (%) þ/þ n (%)
Patient 50 (45.5) 28 (25.5) 32 (29.1)
Control 33 (36.3) 30 (33) 28 (30.8)
The Pvu II genotype frequency distributions were compared with 2
test.
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subjects.31 Normal levels of apo AI found in our dia-
betic group may be because TAG-containing HDL are
better substrates for hepatic lipase, so the lipid-poor
apo AI is more rapidly cleared from the circulation.32
Some previously published results suggest that the
LPL þ/þ genotype is associated with an unfavourable
plasma lipid profile.15,20 In contrast to previous
reports, the Pvu II þ/þ genotype was not found to cor-
relate with unfavourable lipid levels in the present
study, whereas NIDDM patients carrying the þ/
genotype were associated with higher apolipoprotein
E, apolipoprotein B, TAG, total cholesterol and
Lp(a) levels. An explanation for this inconsistency
could be based on the different genetic background
of this cohort. It is also likely that the higher animal
fat intake of the Turkish subjects could mask the effect
of LPL polymorphism.
Differential gene analysis showed the importance
of investigating clinical characteristics for mutations
of coding and non-coding nucleotide sequences.
Intron gene polymorphisms do not affect phenotype
characteristic of the mature protein, but they could
affect the maturation and turnover of mRNA, its size,
translatability, and the nature and number of the pro-
tein products formed.33 Such polymorphisms in
nucleic acids can be readily detected if they lead to
an alteration at the restriction sites. The relation of
NIDDM and Pvu II RFLP polymorphism of the LPL
gene has been investigated in different populations.
An association between the extent of NIDDM and
the LPL–Pvu II polymorphism was reported in
European,34 and Spanish18 subjects, whereas Pvu II
polymorphism did not exhibit any significant
association with NIDDM in a Chinese population.19
Our results are in agreement with the findings of Shen
Table 4. Effects of LPL gene Pvu II polymorphism on clinical parameters in non-insulin dependent diabetes mellitus patients and control
subjects
LPL gene Pvu II polymorphism
Patients þ/ (50) / (28) þ/þ (40) p
Glucose (mmol l1) 9.98 0.58 9.18 0.62 9.67 0.68 n.s.
Total cholesterol (mmol l1) 5.61 0.17 5.26 0.24 5.37 0.18 n.s.
Triacylglycerol (mmol l1) 2.55 0.48 1.60 0.14 1.66 0.13 <0.05
Apolipoprotein E (mg l1) 48.56 3.49 38.35 2.32 42.07 2.31 <0.05
Apolipoprotein AI (g l1) 1.46 0.038 1.37 0.055 1.43 0.047 n.s.
Apolipoprotein B (g l1) 1.19 0.072 1.14 0.044 1.12 0.045 n.s.
Lp(a) (g l1) 0.15 0.026 0.13 0.03 0.13 0.021 n.s.
Controls þ/ (33) / (30) þ/þ (28)
Glucose (mmol l1) 3.54 0.20 3.52 0.14 3.69 0.14 n.s.
Total cholesterol (mmol l1) 5.37 0.25 5.40 0.22 5.42 0.23 n.s.
Triacylglycerol (mmol l1) 1.75 0.13 1.68 0.14 1.74 0.19 n.s.
Apolipoprotein E (mg l1) 47.83 3.18 42.98 2.13 45.76 3.36 n.s.
Apolipoprotein AI (g l1) 1.41 0.04 1.42 0.056 1.40 0.04 n.s.
Apolipoprotein B (g l1) 1.15 0.05 1.10 0.054 1.06 0.052 n.s.
Lp(a) (g l1) 0.15 0.025 0.17 0.041 0.18 0.028 n.s.
Values are represented as meanSE. n.s., not statistically significant.
Table 5. Association of risk factors with non-insulin dependent
diabetes mellitus by multiple logistic regression analysis
All
 SE OR p
Sex 0.50 1.157 0.606 0.665
BMI 0.057 0.090 1.059 0.521
Plasma glucose 4.908 1.226 135.406 0.000*
Cholesterol 0.255 0.176 0.775 0.142
Triacylglycerol 0.730 0.573 2.074 0.203
Apolipoprotein E 0.192 0.060 0.825 0.001*
Apolipoprotein AI 0.223 1.686 0.800 0.895
Apolipoprotein B 4.173 2.097 64.910 0.047*
Smoking habit 11.72 29.851 1.229 0.695
LPL
(/) 1.691 1.020 0.184 0.097
(þ/) 0.353 1.093 0.703 0.747
(þ/þ) 20.647 6.719 0.262 0.240
The multivariate logistic regression model included sex, BMI,
plasma glucose, cholesterol, triacylglycerol, apolipoprotein E,
apolipoprotein AI, apolipoprotein B, smoking habit, and LPL–Pvu
II genotype variables.  indicates estimated coefficient; SE,
standard error; OR, adjusted odds ratio. *Statistically significant.
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et al.19 in that no association between Pvu II and
NIDDM was observed.
A study carried out in Spanish subjects had compar-
able gene frequencies for the Pvu II genotype distribu-
tion in diabetic patients and controls18 in which a
higher frequency of the þ/ genotype in patients with
NIDDM was observed, whereas, Shen and cowor-
kers19 failed to show a significant difference in Pvu
II genotype frequencies between the NIDDM and con-
trol individuals they studied. In our study we did not
find any significant difference among the patient and
control groups when Pvu II genotype frequencies
were taken into account.
In conclusion, LPL–Pvu II polymorphism was not
found to be a genetic risk factor for non-insulin depen-
dent diabetes mellitus, whereas the þ/ genotype was
found to be more associated with higher TAG and apo
E levels than the þ/þ and / genotypes in this
selected study group.
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